Data-Governance-Trends-2025-2026-An-Apptad-Perspective (opens in new tab)Download (opens in new tab)

Data Governance Trends 2025 – 2026: An Apptad Prespective
Related Insights

From Black Box to Glass Box: A Practical Playbook for Explainable AI
AI you can't explain is AI you can't deploy. A risk-tiered playbook for explainable AI in 2026 — from SHAP and counterfactuals to reasoning traces for autonomous agents — built for the new regulatory reality.

Intelligent Data Stewardship for Financial Services
Master data stewardship in a bank always ran on a queue a human had to clear. In 2026 that changed: Reltio shipped autonomous stewardship agents, Informatica announced the first Agentic Multidomain MDM, and SAP acquired Reltio to anchor its AI strategy. This piece maps where autonomous stewardship lands first in financial services — KYC onboarding, AML golden sources, BCBS 239 risk-data aggregation, and reference data — why the data foundation still decides the outcome (99% plan agents, only 11% are in production), and how the steward's role moves from clearing queues to governing exceptions.

Real World Evidence at Scale: The Data Foundation FDA Is Now Demanding
In March 2026 the FDA adopted ICH M14, completing real-world evidence's transition into a first-class regulatory pathway. Roughly a quarter of FDA label expansions in 2022-2024 were supported by RWE, with oncology driving nearly half of those approvals. The shift has exposed a structural problem: the data foundation underneath RWE — patient master, drug master, provider master, and cross-source identity resolution — is not ready for the standard the agency is now applying. This piece explains why RWE at scale is a master data problem, not an analytics one, and what pharma data and regulatory leaders should do in their next ninety days.
Ready to apply these ideas to your business?
Tell us where you're stuck. A senior consultant will reply within one business day with a concrete next step.